The study, which was presented today at the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia, found that low concentrations of TB drugs were common in the population, regardless of HIV status.
However, when people also had advanced HIV disease, concentrations of some of the TB drugs were significantly lower — which could have contributed to poorer treatment outcomes. However, having a low level of pyrazinamide, in particular, was independently associated with having a worse outcome on treatment.
For the full text of this article see here http://www.aidsmap.com/en/news/7616F1CB-0266-4B9A-AE97-5B7DE7B87272.asp
